Long-Term Sustained Disease Control with Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is a rare and difficult-to-treat cutaneous malignancy with a poor prognosis. Treatment protocols for localized MCC are well established. Until recently, metastatic MCC has generally been treated with chemotherapy, which was often associated with poor clinical responses an...
Main Authors: | Deborah Zihler, Kathrin Vollmer, Antonio Cozzio |
---|---|
Format: | Article |
Language: | English |
Published: |
THE HEALTHBOOK COMPANY LTD.
2019-09-01
|
Series: | healthbook TIMES. Oncology Hematology |
Subjects: | |
Online Access: | https://onco-hema.healthbooktimes.org/article/24206-long-term-sustained-disease-control-with-immunotherapy-in-chemotherapy-refractory-merkel-cell-carcinoma |
Similar Items
-
Long-Term Sustained Disease Control with Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma
by: Deborah Zihler, et al.
Published: (2019-09-01) -
Epidemiology of Merkel Cell Polyomavirus Infection and Merkel Cell Carcinoma
by: Steffi Silling, et al.
Published: (2022-12-01) -
T-Cell Mediated Immunity in Merkel Cell Carcinoma
by: Kelsey Ouyang, et al.
Published: (2022-12-01) -
Merkel Cell Polyomavirus (MCPyV) and Cancers: Emergency Bell or False Alarm?
by: Maria Georgia Dimitraki, et al.
Published: (2022-11-01) -
Promoter activity of Merkel cell Polyomavirus variants in human dermal fibroblasts and a Merkel cell carcinoma cell line
by: Ibrahim Abdulsalam, et al.
Published: (2020-04-01)